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BACKGROUND: One of the most promising markers of
allergic inflammation is eotaxin, which has a selec-
tive influence on the migration of eosinophils. Its
serum content significantly correlates with the in-
tensity of allergic symptoms, so it might be interest-
ing to know whether vaccination has any influence
on serum expression of this chemokine.
Aims: Comparison of the humoral response to influ-
enza vaccine and post-vaccination changes in the
serum eotaxin level in patients with allergic bron-
chial asthma and healthy controls.
Methods: Forty-two asthmatics and 45 healthy indi-
viduals were vaccinated with a single dose of influ-
enza subunit vaccine (Influvac). The serum eotaxin
level and the antibody response to haemagglutinin
(HI) and neuraminidase (NI) glycoproteins were
measured before and after vaccination.
Results: A significant increase of geometric mean
titres of HI and NI was observed in both groups.
There were no significant differences between the
groups in meanfold increase of HI and NI titres,
response rate and protective level of HI. After vacci-
nation, a significant decrease of the mean serum
eotaxin value was observed in patients with asthma
(149.49 /71.0 versus 125.19 /67.0, p /0.0017), while
no similar effect was present in healthy individuals
(153.49 /56.9 versus 159.39 /54.4, p /0.5).
Conclusions: The results indicate that in patients with
allergic bronchial asthma influenza vaccinations
assure efficient protective antibody level and mod-
ulate the serum level of eotaxin.
Key words: Inﬂuenza vaccination, Eotaxin, Asthma, Al-
lergy
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Introduction
Influenza is one of the most common respiratory tract
diseases. Infections with influenza virus can cause
exacerbations of bronchial asthma and, in conse-
quence, can lead to life-quality impairment and
higher mortality in patients with asthma.
1 3 Although
vaccinations are considered the most efficacious
method of providing protection against influenza in
most people, there are some data suggesting that
influenza vaccinations do not bring about effective
anti-virus immunization.
4 6 On the other hand, it
might be interesting to know whether vaccination has
any influence on serum expression of inflammation
cytokines. One of the most promising markers of
allergic inflammation is eotaxin, which has a selective
influence on migration of eosinophils.
7 9 Many
authors have revealed that the concentration of
eotaxin is higher in patients with allergic bronchial
asthma.
10,11 In this study we assess humoral antibody
response and changes in serum eotaxin level after
influenza vaccinations in healthy people and inpati-
ents with allergic bronchial asthma.
Materials and methods
The study population comprised 42 subjects (22
females and 20 males) with stable allergic bronchial
asthma with a mean age of 46.6 years (standard
deviation, 18.0), and 45 healthy controls (32 females
and 13 males) with a mean age of 44.5 years
(standard deviation, 13.5).
Subjects with bronchial asthma had a history of
intermittent wheeze, chest tightness, cough and
sputum production either spontaneously, after aller-
gen exposure, or after exercise, together with rever-
sible airflow limitation documented within 6 months
preceding the study.
12 Respiratory symptoms were
controlled with b2-adrenergic drugs and inhaled
steroids in an equivalent dose of less than 800 mgo f
budesonide per day. The allergic origin of the
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195complaints has been proven by positive results of the
skin prick tests and a significant serum level of
immunoglobulin E specific to common aeroallergens.
Each subject from the healthy control group had a
normal value of pulmonary function tests, a negative
history of allergic diseases and negative results of the
skin prick tests.
People with a smoking habit, hypersensitivity to
eggs, chicken, influenzal proteins or evidence of
neoplasmatic disease, leukaemia and any other sig-
nificant immunocompromised status were not in-
cluded into the study. Also, individuals who had
been vaccinated against influenza during the 2 years
before the study, or had had symptoms of any
infection or had received antivirals or immunosu-
pressive drugs during 30 days before the recruitment
were not registered.
Each subject received an intramuscular single dose
of influenza subunit vaccine (Influvac; Solvay Phar-
maceuticals GmbH, Brussels, Belgium). The vaccine
contained 15 mg of haemagglutinin (HI) of each of
the following virus strains: A/New Caledonia/20/99
(H1N1), A/Moscow/10/99 (H3N2) and B/Sichuan/
379/99. The antibody response to HI and neuramini-
dase (NI) glycoproteins of influenza virus and the
eotaxin level were measured in serum collected
during 24 h before and 6 weeks after vaccination.
All samples were stored at   /208C until use. An
enzyme-linked immunosorbent assay method was
used for serum eotaxin measurements (ELISA R&D
kits, USA).
13 After non-specific serum inhibitor in-
activation (by heating and treatment with receptor-
destroying enzyme), anti-haemagglutinin and anti-
neuraminidase levels were determined by the stan-
dardized inhibition tests and were expressed as the
last serum dilution showing complete inhibition.
14,15
For expression of humoral response in each studied
group the following parameters were used:
. geometric mean titres (GMT) of HI and NI
antibodies (titreB /1:10 was arbitrarily set at 5);
. meanfold increase of GMT and response rate
(i.e. the proportion of subjects showing at
least a fourfold increase in HI antibody titre);
and
. protection rate (i.e. the proportion of subjects
showing HI antibody level ] /1:40).
Quantitative, normally distributed data were analysed
by t-test. Chi-squared and Wilcoxon’s signed-rank
sum tests were used for comparative analysis of non-
paired, non-normally distributed variables. Correla-
tion coefficients were calculated for assessment of the
relationship between humoral response and serum
eotaxin concentration. pB /0.05 was considered sig-
nificant.
The study protocol was approved by the ethics
committee of the Military School of Medicine in
Warsaw (Poland).
Results
The results of humoral response are summarized in
Tables 1 and 2. Six weeks after immunization, there
was a significant increase of the GMT of HI and NI
antibodies to the three virus antigens in both studied
groups (Wilcoxon’s rank-sum test, pB /0.05). The
meanfold increase of HI and anti-neuraminidase titres
ranged accordingly: 5.2 /23.7 and 4.3 /11.1 for the
subjects with asthma; and 8.2 /14.1 and 7.1 /10.2 for
the healthy controls. There were no significant
differences between the asthmatics and normals in
response rate to vaccination and the proportion of
subjects with the protection level of HI before
and after vaccine administration (chi-squared test,
p  /0.05).
After vaccination a significant decrease of the mean
serum eotaxin value was observed in the patients
with asthma (149.49 /71.0 versus 125.19 /67.0,
p  /0.0017), while no similar effect was present in
the healthy individuals (153.49 /56.9 versus 159.39 /
54.4, p  /0.5) (Fig. 1). No significant linear correlation
was found between changes in serum eotaxin con-
tent and meanfold increase of HI and NI antibody
titres after vaccination (p  /0.05).
Discussion
Respiratory tract infections, especially infection with
influenza virus, can trigger exacerbations of bron-
chial asthma, and can lead to a higher frequency of
illness-related hospitalizations and higher death
rate.
16 18 Therefore, annual vaccinations against
influenza in patients with chronic pulmonary dis-
eases are recommended by The Advisory Committee
on Immunization Practices.
1 Safety and good toler-
ability of vaccines has been proven in many
studies;
19 22 however, there are still scarce data on
whether immune response after vaccination in pa-
tients with bronchial asthma is comparable with that
in healthy people. The main protective effect of
influenza vaccination is related to antibody response
to HI antigen of virus.
23 Depending on their con-
centration, HI antibodies inhibit effectively the at-
tachment of virus to target cell membrane receptors
and provide prevention against serious illness. Pro-
tection studies have shown that anti-haemagglutinin
antibody titres ] /40 can be considered as the safety
threshold beyond which serious influenza infection is
rather unlikely.
24 According to the settlement of the
Commmittee for Proprietary Medicinal Products and
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196 Mediators of Inflammation Vol 13  2004the Commission of the European Community, after
influenza vaccination the protection rate should
amount to at least 70% (60% in patients older than
60 years) of vaccinees and the response rate should
be at least 40% (30% in people older than 60 years) of
vaccinees.
25,26
In the present study no significant differences in
the proportion of subjects protected were observed
between the healthy individuals and the patients with
allergic bronchial asthma after influenza vaccination.
Moreover, the protection rate reached the recom-
mended level in each tested group. The response rate
value was also comparable in these groups and
reached the recommended value. Significant increase
of antineuraminidase antibodies level, responsible for
inhibition of the release of mature viral particles from
infected cells,
27 was present after influenza vaccina-
tion in both groups.
It is noteworthy that the serum eotaxin level
significantly decreased after vaccination in the pa-
tients with bronchial asthma. An increased expres-
sion of eotaxin within the peripheral airways of lungs
of the asthmatic subjects was shown, suggesting that
this chemokine contributes to the small airways and
peripheral lung inflammation in asthma.
11 Some
studies indicate that the plasma eotaxin concentration
significantly rises in the case of exacerbation of
allergic symptoms.
28,29 Thus, decreasing the serum
eotaxin content can be an additional health benefit of
vaccination for patients with allergic asthma. It seems
probable that the mechanism of serum eotaxin
depletion after vaccination is associated with stimula-
tion of different subsets of T-helper (Th) lympho-
cytes.
30 One type of CD4
  clone (Th1) produces,
among others, interferon (IFN)-g; a second type
(Th2) produces interleukin (IL)-4 and IL-5.
31,32 It is
well known that IFN-g plays a pivotal role in the
defence against viruses and its expression signifi-
cantly increases during viral infections or after anti-
viral vaccinations.
33,34 In vitro analysis of the me-
chanisms of eotaxin generation by Th1-/Th2-derived
cytokines revealed that Th2-type cytokine (i.e. IL-4)
induced eotaxin production, while Th1-type cytokine
(IFN) inhibited eotaxin generation.
35 This mechanism
seems to be a good explanation for downregulation
of the serum eotaxin level in subjects with asthma,
but should be proved in following studies. We did
not observe any significant correlation between
humoral response and serum eotaxin changes in
asthmatics and healthy individuals. However, some
data indicate also that there is no relationship
between antibody response to influenza vaccine
and IFN-g.
34
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The results of this trial indicate that the immune
response to influenza vaccine in asthmatics is com-
parable with those in healthy individuals. Moreover,
in patients with allergic asthma, vaccinations can
cause depletion of the serum level of eotaxin */ a
strong primary mediator of tissue eosinophilia. The
mechanism that makes influenza vaccination have
different influence on serum eotaxin level in healthy
people and subjects with allergic asthma is unclear,
and requires further study.
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